Numan Raises $60 Million to Fuel Preventive Health Expansion and Reach New Frontiers

London-based digital health company Numan has secured US$60 million in fresh funding in 2025, marking a major step forward in its efforts to scale preventive care and expand into underserved healthcare segments. This latest financing is part of an extension of its Series B round.

The funding package comprises $30 million in equity led by Big Pi Ventures through its new Growth Fund strategy, joined by Endeavor Catalyst, White Star Capital, and Novator Partners. Alongside that equity portion, HSBC Innovation Banking UK provided $27 million in growth capital.

This financing comes on the heels of a very strong financial year. By the end of 2024, Numan’s revenue had more than doubled year-on-year to approximately US$90 million. The company also reported that it achieved profitability in the last 18 months, and it is on track for an even greater leap forward in 2025. Its growth forecast is around 150% year-over-year.

Numan delivers care to over 650,000 patients through its platform, covering a range of services including obesity management, men’s health, diagnostics, and behavioural health coaching. It also maintains a net promoter score (NPS) of 68, well above average for healthcare services, which reflects strong patient satisfaction and engagement.

With this new capital, Numan plans several strategic moves. It will expand its clinical offerings into female health, bolstering services previously more focused on men’s health. It will also deepen its preventive care and screening programs, scale the technology and infrastructure required to serve more patients, accelerate its AI-driven tools such as coaching, expand marketing efforts, and consider international expansion.

Leadership at Numan emphasizes that the company’s mission remains providing personalised, preventative health at scale. CEO Sokratis Papafloratos has stated that recent demand from users, especially for obesity and hormonal health solutions, has outpaced expectations, leading to the push toward more diversified care including female health and more powerful digital health tools.

Among investors, Big Pi Ventures takes a lead role, not only in driving the equity portion of the round but also in backing Numan’s long-term vision. Other investors like Endeavor Catalyst, White Star Capital, Novator Partners, and HSBC Innovation Banking UK are joining the effort to help the company scale.

The funding also reflects wider trends in digital health. There is growing enthusiasm for preventive and proactive healthcare models, especially with strong demand for obesity treatments, more accessible hormonal health care, and remote diagnostics. The surge in interest in weight-loss medications such as GLP-1s has also contributed to demand for services like those Numan provides.

Numan has indicated that part of this investment will go toward setting up operations in new regions. One noted expansion is into female health services which were relatively undeveloped at the company prior to this funding, and there is an ambition to break into new geographies while continuing to optimise its clinical and behavioural health support tools.

Numan’s US$60 million raise reflects both its strong recent performance and ambitious plans to broaden its scope. With equity and growth capital backing from high-profile health-investment firms, the company looks poised to scale its preventive health platform, expand into female health, improve AI-powered care, pursue international growth, and continue delivering high patient satisfaction.